Olutasidenib is a selective isocitrate dehydrogenase-1 (IDH1) inhibitor used in the treatment of adult patients with relapsed or refractory acute myeloid leukemia who carry a susceptible IDH1 mutation.… Read more
Olutasidenib is a selective isocitrate dehydrogenase-1 (IDH1) inhibitor used in the treatment of adult patients with relapsed or refractory acute myeloid leukemia who carry a susceptible IDH1 mutation. By inhibiting this mutated metabolic enzyme, the drug reduces the production of the oncometabolite 2-hydroxyglutarate, helping to restore normal cellular differentiation processes in leukemic cells. The Olutasidenib category provides essential reference standards, including the parent drug, its brominated analog, and the nitrosamine impurity N-Nitroso Olutasidenib. These high-quality compounds are utilized by pharmaceutical laboratories for critical analytical applications such as impurity profiling, the validation of analytical methods, and rigorous quality control protocols during the synthesis and development of this targeted therapy. Researchers and analytical chemists rely on these reference materials to ensure the precision of identification and quantification processes in regulatory and clinical environments.